Research programme: hepatitis C virus NS4b protein inhibitors - Genelabs

Drug Profile

Research programme: hepatitis C virus NS4b protein inhibitors - Genelabs

Latest Information Update: 02 Apr 2012

Price : $50

At a glance

  • Originator Genelabs Technologies
  • Class Imidazoles; Oxazolidinones; Pyridines; Small molecules
  • Mechanism of Action Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Hepatitis C

Most Recent Events

  • 29 Mar 2012 Early research is ongoing in USA
  • 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
  • 04 Nov 2008 Pharmacodynamics data from in vitro studies in Hepatitis C presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top